Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

79.17 +0.70 (+0.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine
Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. 
Via Stocktwits
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
From AstraZeneca
Via Business Wire
White House Eyes Up to 250% Drug Tariffs In Bid To Reclaim US Pharma Supply Chain
White House trade adviser Peter Navarro discusses tariffs on pharma imports under a "Section 232" trade investigation. 
Via Benzinga
Topics World Trade
The Specter of Stagflation: Trump's Tariffs Cast a Long Shadow Over the U.S. Economy
Economists and investors are increasingly sounding the alarm over the growing risk of "stagflation," a perilous economic phenomenon characterized by high inflation coupled with stagnant economic... 
Via MarketMinute
Topics Economy Government Supply Chain
AstraZeneca CEO Calls US Drug Pricing Model ‘Unsustainable’ — Pushes for Global Rate Alignment
Via Stocktwits
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
Stagflation Specter Haunts Markets as Economic Data Disappoints
The global financial markets are grappling with a growing sense of unease as recent economic data points to a troubling confluence of high inflation and sluggish growth, rekindling fears of... 
Via MarketMinute
Topics Economy Stocks World Trade
1 Small-Cap Biotech Stock Poised for a Breakout
This developmental biotech is nearing a key inflection point. 
Via The Motley Fool
Topics Economy
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers
Via Stocktwits
Earnings Scheduled For July 29, 2025
 
Via Benzinga
AstraZeneca Earnings Preview
 
Via Benzinga
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca
Via Stocktwits
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose. 
Via Benzinga
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Why AstraZeneca Stock Was Topping the Market on Tuesday
Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line. 
Via The Motley Fool
AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook
AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer. 
Via Benzinga
Topics Earnings
AstraZeneca results: H1 and Q2 2025
From AstraZeneca
Via Business Wire
Why Is Micro-Cap AIM ImmunoTech Stock Surging?
AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients. 
Via Benzinga
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
From AstraZeneca
Via Business Wire
5 Dividend Stocks to Hold for the Next 20 Years
Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them! 
Via The Motley Fool
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG. 
Via Benzinga
What's Driving the Market Sentiment Around AstraZeneca?
 
Via Benzinga
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline. 
Via Benzinga
Dow Futures Edge Lower As Investors Exercise Caution After S&P 500’s Record High: GM, KO, NXPI, AZN Among Stocks To Watch
While Dow Jones futures were down 0.01% at the time of writing, the S&P 500 futures fell 0.09%. 
Via Stocktwits
Topics ETFs Government Stocks
AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters
At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia. 
Via Stocktwits
Topics Artificial Intelligence Government World Trade
AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer
AstraZeneca's Tagrisso with chemo significantly improves survival and progression-free outcomes in EGFR-mutant NSCLC, final trial data shows. 
Via Benzinga
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
From AstraZeneca
Via Business Wire
TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.